ClinicalTrials.gg
RecruitingNCT05214105PREMIERUpdated Dec 14, 2023

The Predictive Capacity of Machine Learning Models for Progressive Kidney Disease in Individuals With Sickle Cell Anemia

An observational study in Sickle Cell Disease and Kidney Diseases, Chronic, sponsored by University of Tennessee. Recruiting at 3 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-12-14.

Sponsored by University of Tennessee · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Jul 2022; still recruiting 4 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 733 studies in Anemia, Sickle Cell with a site in United States — 134 open to participants now, 185 under way, 16 of them phase 3. Anemia, Sickle Cell · United States.

Planned enrollment
35th of 168
400 · median 100
Started
2022
with 40 others
Observational
168 of 733
34 open now
Primary completion
2026-01
later than 28 of 182 live
Registered
572nd of 733
by date

Among the 733 studies in Anemia, Sickle Cell with a site in United States, this one is the 35th largest by planned enrollment of the 168 observational ones that give a count, is one of 41 that started in 2022, is one of 168 observational ones, reaches primary completion later than 28 of the 182 other live ones, and was the 572nd registered.

Anemia, Sickle Cell

1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

134 of the 733 studies in Anemia, Sickle Cell with a site in United States are open now. Recruiting first, the newest first:

129 more — sign in →

All 134 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 733 studies in Anemia, Sickle Cell with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter prospective, longitudinal cohort study which will evaluate the predictive capacity of machine learning (ML) models for progression of CKD in eligible patients for a minimum of 12 months and potentially for up to 4 years.

Read the detailed description

Sickle cell disease (SCD) is characterized by a vasculopathy affecting multiple end organs, with complications including ischemic stroke, pulmonary hypertension, and chronic kidney disease (CKD). Albuminuria, an early measure of glomerular injury and a manifestation of CKD, is common in SCD and predicts progressive kidney disease. Kidney function decline is faster in SCD patients than in the general African American population. The prevalence of rapid decline, commonly defined as an estimated glomerular filtration rate (eGFR) decline of >3 mL/min/1.73 m2 per year, is \~ 31% in SCD, 3-fold higher than in the general population. Furthermore, high-risk Apolipoprotein 1 (APOL1) variants are associated with an increased risk of albuminuria and progression of CKD in SCD. It is well recognized that kidney disease, regardless of severity, is associated with increased mortality in SCD. The investigators have recently observed that rapid eGFR decline is also independently associated with increased mortality in SCD. Early identification of patients at risk for progression of CKD is important to address potentially modifiable risk factors, slow eGFR decline and reduce mortality.

The investigators have previously reported that machine learning (ML) models can identify patients at high risk for rapid decline in kidney function. In this study, the investigators propose the conduct of a prospective, multi-center study to build a ML-based predictive model for progression of CKD in adults with SCD. A model with high predictive capacity for progression of CKD not only affords risk-stratification, but also offers opportunities to modify known risk factors in hopes of attenuating kidney function loss and decreasing mortality risk.

The overall hypothesis is that ML models utilizing clinical and laboratory characteristics, additional biomarkers and genetic assessments have a higher predictive capacity for progression of CKD than persistent albuminuria alone in adults with sickle cell anemia.

03

Conditions studied

  • Sickle Cell Disease
  • Kidney Diseases, Chronic

Keywords

  • Machine Learning Models
  • Sickle Cell Disease
  • Chronic Kidney Disease
  • eGFR
  • Anemia, Sickle Cell
  • Albuminuria
  • Renal Insufficiency, Chronic
  • Renal Insufficiency
  • APOL1
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Four hundred patients with SCD (HbSS or HbSB0 thalassemia) between the ages of 18 and 65 who meet the eligibility criteria and provide consent to participate in the study, will be enrolled in this prospective longitudinal trial.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. HbSS or HbSβ0 thalassemia, 18 - 65 years old;
  2. non-crisis, "steady state" with no acute pain episodes requiring medical contact in preceding 4 weeks;
  3. ability to understand the study requirements.

Exclusion criteria

Exclusion Criteria:

  1. pregnant at enrollment;
  2. poorly controlled hypertension;
  3. long-standing diabetes with suspicion for diabetic nephropathy;
  4. connective tissue disease such as systemic lupus erythematosus (SLE);
  5. polycystic kidney disease or glomerular disease unrelated to SCD;
  6. stem cell transplantation;
  7. untreated (HIV), or C infection; h) history of cancer in last 5 years; i) End-stage renal disease (ESRD) on chronic dialysis; j) prior kidney transplantation.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Patients with sickle cell anemia

    Prospective longitudinal study of patients with sickle cell anemia

    Other: Biospecimen/DNA collection and analysis

Interventions

  • OtherBiospecimen/DNA collection and analysis

    Patients will be followed longitudinally with collection of CBC and chemistries as well as research biomarkers (urine, plasma, and genomic materials).

06

What researchers measure

Primary outcomes

  1. Develop two separate predictive models for progression of CKD (eGFR <90 mL/min/1·73 m2 and ≥25% drop in eGFR from baseline) and rapid eGFR decline (eGFR loss >3·0 mL/min/1·73 m2 per year) over the 12 months following the baseline clinic evaluation.

    At each visit following the first 12 months, rate of eGFR change will be calculated using data from current and earlier visits.

    Time frame: 12 months

Secondary outcomes

  1. Alternate definitions of CKD progression as eGFR decline <90 mL/min/1·73 m2 and ≥50% drop in eGFR from baseline, and rapid eGFR decline as eGFR loss >5·0 mL/min/1·73 m2 per year will be evaluated.

    At each visit following the first 12 months, rate of eGFR change will be calculated using data from current and earlier visits.

    Time frame: 12 months

  2. Evaluate the effect of APOL1 on the predictive capacity of ML models. Genomic DNA will be extracted from whole blood collected at baseline visits using standard techniques and genotyping will be performed as previously described.

    At each visit following the first 12 months, rate of eGFR change will be calculated using data from current and earlier visits

    Time frame: 12 months

07

Study locations

2 of 3 sites recruiting
  • University of Illinois at Chicago
    Chicago, Illinois 60612, United States
    Recruiting
    • Santosh Saraf, MD · Contactssaraf@uic.edu
    • Santosh Saraf, MD · Principal investigator
  • Wake Forest University
    Winston-Salem, North Carolina 27109, United States
    Not yet recruiting
  • The University of Tennessee Health Science Center
    Memphis, Tennessee 38104, United States
    Recruiting
    • Kenneth Ataga, MD · Contactkataga@uthsc.edu · 901-448-2813
    • Kenneth Ataga, MD · Principal investigator
    • Robert Davis, MD · Sub investigator
    • Laila Elsherif, PhD · Sub investigator
    • Ugochi Ogu, MD · Sub investigator
    • Marquita Nelson, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — De-identified data will be provided to other academic investigators, upon request, for the purposes of non-commercial research, utilizing institutional Material Transfer Agreement (MTA).

Supporting information: Study protocol, Clinical study report, Analytic code

Time frame: From time of first patient enrollment to up to 7 years after completion of study.

Access criteria: Requests for data from academic investigators will be approved by the Executive Committee of the PREMIER Study. Following approval, de-identified data will be shared in a secure manner.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Jan 2026, 42 months after the start.

Of 130 non-industry observational studies under Anemia, Sickle Cell, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 109. This study's planned 42 months is below that.

Counting every sponsor, half of 139 studies reached it within 49 months; a quarter within 24 and three quarters within 109.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2021
First posted
Jan 28, 2022
StartActual
Jul 5, 2022
Primary completionEst.
Jan 31, 2026
CompletionEst.
Jan 31, 2026
Last update
Dec 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05214105
Responsible party
Kenneth Ataga MD (Principal Investigator, University of Tennessee) — Principal investigator
First posted
Jan 28, 2022
Start date
Jul 5, 2022
Primary completion
Jan 31, 2026 (estimated)
Completion
Jan 31, 2026 (estimated)
Last update
Dec 14, 2023

Study contacts

Kenneth I Ataga, MD
Contact
kataga@uthsc.edu
901-448-2813
Santosh Saraf, MD
Contact
ssaraf@uic.edu
312-996-5680
Kenneth I Ataga, MD
principal investigator · The University of Tennessee Health Science Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion